Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561883 | 0.88 | KCNH2 (0.61) | KCNH2BACE1BACE2MAPTOPRM1 | |
| SCHEMBL14497610 | 0.88 | KCNH2 (0.61) | KCNH2BACE1BACE2MAPTOPRM1 | |
| SCHEMBL14497609 | 0.88 | KCNH2 (0.61) | KCNH2BACE1BACE2MAPTOPRM1 | |
| SCHEMBL15154101 | 0.88 | SIGMAR1 (0.48) | KCNH2BACE1BACE2MAPTCTSD | |
| SCHEMBL6560821 | 0.83 | KCNH2 (0.52) | KCNH2MAPTOPRM1GRIN2BNPY1R | |
| Hydrochloric Acid SCHEMBL6561791 | 0.82 | KCNH2 (0.49) | KCNH2BACE1BACE2MAPTOPRM1 | |
| SCHEMBL15154321 | 0.77 | KCNH2 (0.49) | KCNH2OPRM1 | |
| SCHEMBL15154053 | 0.74 | KCNH2 (0.41) | KCNH2BACE1BACE2CTSDPRMT5 | |
| SCHEMBL19632855 | 0.72 | BACE1 (0.44) | BACE1BACE2MAPTOPRM1OPRL1 | |
| SCHEMBL15154012 | 0.72 | KCNH2 (0.47) | KCNH2BACE1BACE2MAPTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458439-B1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11192857-B2 | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use | ALERE SAN DIEGO, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190292148-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3458439-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | Alere San Diego, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201314-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-0931062-B1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6140137-A | METABOLITE LINKED TO POLYPEPTIDE FOR ANALYSIS AND ANTIBODY PRODUCTION; MONITORING COMPLIANCE WITH METHADONE TREATMENT | MICROGENICS CORPORATION (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0931062-A1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998054133-A1 | CONJUGATES AND SPECIFIC IMMUNOASSAYS FOR THE METHADONE METABOLITE 2-ETHYLIDINE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE | MICROGENICS CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192857-B2 | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use | DPYSL2, DNPEP, DPYSL3 | KCNH2 4297/4885BACE1 3051/4885BACE2 1749/4885 |
| US-20190292148-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | DPYSL2, DNPEP, DPYSL3 | KCNH2 4297/4885BACE1 3051/4885BACE2 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.